1. Search Result
Search Result
Results for "

CLK2+inhibitor

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144875

    CTX-712

    CDK Cancer
    Rogocekib is an orally effective CLK 2 inhibitor, with an IC50 of 1.4 nM, showing anti-tumor activity [2].
    Rogocekib
  • HY-108709
    CC-671
    1 Publications Verification

    CDK Cancer
    CC-671 is a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor with IC50s of 0.005 and 0.006 μM for TTK and CLK2, respectively.
    CC-671
  • HY-113825

    CDK Cancer
    CLK1/2-IN-2 is CLK1 and CLK2 inhibitor with IC50 values of 16 nM and 45 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities [1] .
    CLK1/2-IN-1
  • HY-113831

    CDK SRPK Cancer
    LK1/2-IN-3 (compound 3) is a potent and selective CLK1 and CLK2 inhibitor with IC50 values of 1.1, 2.1, 130, 260, 260 nM for CLK1, CLK2, SRPK1, SRPK2, SRPK3, respectively. CLK1/2-IN-3 shows anti-proliferative activity. CLK1/2-IN-3 reduces the levels of endogenous phosphorylated SR proteins and increases the expression of S6K mRNAs .
    CLK1/2-IN-3
  • HY-125201

    CDK Inflammation/Immunology
    Indazole 1 is a potent CDC2-like kinase 2 (CLK2) inhibitor (IC50=12.3 nM). Indazole 1 inhibits the phosphorylation of SR proteins (e.g., SRSF1, SRSF3) and modulates alternative splicing of Wnt signaling-related genes. Indazole 1 is promising for research of osteoarthritis .
    Indazole 1
  • HY-168209

    Wnt CDK Apoptosis Cancer
    LBM22 is a CDC2-like kinase 2 (CLK2) inhibitor with the IC50 of 3.9 nM. LBM22 has antiproliferative activity and inhibits serine/arginine-rich (SR) protein phosphorylation. LBM22 down-regulates the expression of Wnt-related proteins and anti-apoptotic proteins and can be used for study of non-small cell lung cancer .
    LBM22
  • HY-113670

    CDK Cancer
    CLK1/2-IN-2 is CLK1 and CLK2 inhibitor with IC50 values of 1.1 nM and 2.4 nM, respectively. CLK1/2-IN-2 exhibits potent anti-cancer activities [1] .
    CLK1/2-IN-2
  • HY-108709R

    Reference Standards CDK Cancer
    CC-671 (Standard) is the analytical standard of CC-671 (HY-108709). This product is intended for research and analytical applications. CC-671 is a dual TTK protein Kinase/CDC2-like Kinase (CLK2) inhibitor with IC50s of 0.005 and 0.006 μM for TTK and CLK2, respectively.
    CC-671 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: